Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
rafeykeith

Petitioners Ask To Add 3 Ailments To Medical Marijuana Program - Hartford Courant

Healthiest Foods of All Time (With Recipes)

healthiest foods, health food, diet, nutrition, time.com stock, red wine, alcohol Several other conditions could be added soon: sickle cell disease; severe psoriasis and psoriatic arthritis; and post-laminectomy syndrome with chronic radiculopathy recurring back pain after surgery. Petitioners asked for those conditions to be added. The state medical marijuana program's board of physicians reviewed them and recommended they be added to the list of existing conditions. The board of physicians declined to add Tourette syndrome. The marijuana program is part of web site the state Department of Consumer Protection, overseen by Commissioner Jonathan A. Harris.
For the original version including any supplementary images or video, visit http://www.courant.com/business/hc-medical-marijuana-connecticut-colitis-20150302-story.html?track=rss

Research and Markets: Chronic Plaque Psoriasis Pipeline Review 2015 - Analysis of 20 Companies & 22 Drug Profiles - Yahoo Finance

Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com .
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cellceutix-expand-skin-product-pipeline-143141096.html

Is This Amgen's Next Big Thing? (AMGN)

psoriasis registry begins severe psoriasis recruiting patients in 2015. The registry, a joint collaboration with the National Psoriasis Foundation and Corrona, LLC, will initially track the drug safety reporting for secukinumab, a new biologic medication by Novartis Pharmaceuticals for moderate-to-severe psoriasis. The Corrona Psoriasis Registry will enroll at least 3,000 people with psoriasis on secukinumab and follow their treatment for at least eight years. Novartis is the first subscriber to the registry and did incur a subscriber fee. To become an investigator in the registry or learn more about it, visit www.psoriasis.org/corrona-registry .
For the original version including any supplementary images or video, visit http://www.prnewswire.com/news-releases/first-independent-us-psoriasis-registry-will-track-drug-safety-and-effectiveness-300041765.html

Cellceutix to Expand Its Skin Product Pipeline - Yahoo Finance

By 2008, the global generic drug market had become worth $81 billion a year,and by 2013 it had eclipsed the $300 billion mark. The rapid adoption of generic drugs has many companies, including Amgen, thinking that a similar multibillion-dollar market may be in the making for generic alternatives to biologic drugs. According to IMS Health, the biologic drugs market is expected to eclipse $200 billion in 2018, and that has industry participants thinking the biosimilars market could be worth as much as $20 billion by 2020. Making a play Amgen is arguably one of the companies most exposed to the threats of biosimilars, but it's also one of the companies best positioned to benefit from them. Among Amgen's biologics that are at risk of losing share to biosimilars is Neupogen, a white-blood-cell booster that is used during chemotherapy. Neupogen lost patent protection in 2013 and had $1.4 billion in sales last year.
For the original version including any supplementary images or video, visit http://www.investopedia.com/articles/markets/030215/amgens-next-big-thing.asp?partner=mediafed

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/research-markets-chronic-plaque-psoriasis-121800165.html

First independent U.S. psoriasis registry will track drug safety and effectiveness -- PORTLAND, Ore., Feb. 26, 2015 /PRNewswire-USNewswire/ --

Serving size: one cup, cooked Nutrition per serving: Recipe from Cooking Light: Lentils with Wine-Glazed Winter Vegetables Ingredients 1 1/2 cups dried lentils 1 teaspoon salt, divided 1 1/2 teaspoons olive oil 2 cups chopped onion 1 1/2 cups chopped peeled celeriac (celery root) 1 cup diced parsnip 1 tablespoon minced fresh or 1 teaspoon dried tarragon, divided 1 tablespoon tomato paste 2/3 cup dry red wine 2 teaspoons Dijon mustard 1/4 teaspoon black pepper Preparation Combine water, lentils, 1/2 teaspoon salt, and bay leaf in a medium saucepan; bring to a boil. Reduce heat, and simmer 25 minutes. Remove lentils from heat, and set aside. Heat olive oil in a medium cast-iron or nonstick skillet over medium-high heat.
For the original version including any supplementary images or video, visit http://time.com/3724505/50-healthiest-foods/

Don't be the product, buy the product!

Schweinderl